Shengli Oilfield oil wells have a good recipe for "longevity"
Novo Nordisk submits Ozempic high-dose 2.0mg in the United States: for intensive treatment
Innovative DMD therapy reaches the key clinical trial endpoint and is expected to submit a new drug early next year...
Kangfang Bio-PD-1 submitted the US listing application: being selected for RTOR, faster than priority review
DMD innovative therapies reach key clinical trial endpoints, new drug applications are expected to be submitted early next year
Express | 5 phase 3 clinical trials have all met the standards, and dual-mechanism diabetes therapy is expected to submit marketing applications this year
Arnold Pharma submits clinical application for new drug AN4005 to FDA
Novartis Q1: Entresto submits US$789 million US listing application for tislelizumab at the end of the year
Amgen's blockbuster monoclonal antibody Tezepelumab submitted to BLA, phase III clinical trial has started in China
[Nature Magazine] Harvard scientists are exploring the mystery of esophageal cancer and ancient viruses. Blocking the ADAR1 enzyme is so important!
Novartis Q1: Entresto submits a substitute mine at the end of the year for US$789 million...
Express | Subcutaneous RNAi Therapy Reached All Phase 3 Clinical Endpoints, New Drug Application Has Been Submitted
Microchip's partner submits Chidamide's listing application in Japan and is accepted
Re-submitting BLA's regenerative therapy, can it break through the challenge of CMC | Yimai Meng broke the news
"Pharmaceutical Speed Reading Service" Biotech re-submitted H-share listing application to the Hong Kong Stock Exchange
Merck/Eisai’s “Immunity + Targeting” combination submits its first application in Japan
Subcutaneous RNAi therapy has reached all phase 3 clinical endpoints and a new drug application has been submitted
Industry | "Coating Industry" magazine celebrates its 60th anniversary in Shanghai: inheriting history and paying tribute to the future
Hengrui Medicine's PD-1 monoclonal antibody anti-cancer new drug submits two more marketing applications
Starting from April, pharmaceutical companies that have not submitted a letter of trust will not be able to participate in new bids or online appeals!